ACT for Chronic Kidney Disease in India: Renoprotective Paracrine Support | ALIV

Chronic kidney disease (CKD) — the progressive loss of kidney function over months to years — affects an estimated 17% of India's adult population and is a leading cause of morbidity and eventual dialysis dependency. The pathological mechanisms driving CKD — tubular hypoxia, interstitial fibrosis, podocyte loss, and chronic glomerular inflammation — have limited pharmacological reversal options beyond optimising the underlying conditions driving CKD (diabetes, hypertension, glomerulonephritis). ACT's renoprotective application targets these mechanisms through the growth factor profile most relevant to kidney tissue: HGF (the primary tubular repair growth factor), VEGF (restoring the peritubular and glomerular microvascular supply), and MSC anti-inflammatory signals (reducing the chronic interstitial inflammatory burden driving fibrosis).

The HGF-Kidney Connection

HGF (Hepatocyte Growth Factor) — despite its name suggesting liver specificity — is the primary mitogenic and anti-apoptotic signal for renal tubular cells. In CKD, the normal HGF response to tubular injury is insufficient to overcome the ongoing damage from hypoxia, oxidative stress, and proteinuria. ACT preparations from bone marrow — which are particularly rich in HGF — deliver a paracrine HGF signal that supports tubular cell survival, stimulates renal progenitor cell activity in the tubular lining, and promotes the anti-fibrotic tubular repair that opposes the progression of interstitial fibrosis. Alongside HGF, VEGF supports the glomerular and peritubular capillary network — reduced peritubular capillary density is a documented driver of tubular hypoxia and CKD progression. See: ACT mechanism.

Patient Selection and Stage

ALIV's CKD ACT programme is appropriate for patients at CKD stages 3 and 4 (eGFR 15–59 ml/min/1.73m²) — where meaningful nephron mass remains for the renoprotective paracrine signals to support. Stage 5 CKD (eGFR below 15) or established dialysis dependency is not a primary ACT application — the nephron mass available for regenerative support is too severely reduced, and transplant evaluation is the appropriate clinical priority. The clinical goal in stages 3–4 is slowing of eGFR decline and preservation of residual function — not reversal of established renal fibrosis, which is not achievable with current regenerative approaches.

Can ACT delay dialysis for CKD patients?

For CKD stage 4 patients with progressive eGFR decline, meaningful slowing of the progression rate may extend the interval before dialysis dependency — providing additional years of quality life without dialysis in responsive patients. This is the clinical goal: meaningful preservation of function for longer, not elimination of the eventual dialysis trajectory in severe CKD. The degree of benefit is variable and individual — some stage 4 patients show stabilisation of eGFR for twelve to eighteen months; others show more modest trajectory changes. The pre-ACT consultation provides the honest individual probability assessment based on current eGFR trend, underlying CKD aetiology, and proteinuria status.

Is ACT safe for patients with reduced kidney function?

The harvest procedure (bone marrow aspiration under local anaesthesia) is generally safe in CKD patients with stages 3–4 function. Medication management requires specific attention: nephrotoxic medications must be avoided; NSAIDs are absolutely contraindicated in CKD; contrast dye for any imaging done in the procedure context requires careful risk assessment. These considerations are all assessed at the pre-ACT consultation for CKD patients, with input from the treating nephrologist.